

Amendments to the Claims:

The following listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Currently Amended) A method ~~for treating or inhibiting invasiveness of~~ metastatic tumor cells of epithelial tissue ~~origin of a subject origin,~~ the method comprising administering to said subject contacting said cells with an antisense molecule, said antisense molecule comprising a nucleotide sequence comprising SEQ ID NO: 7 or a fragment thereof that which hybridizes to an RNA sequence of a thrombin receptor, thereby interfering with the process of mRNA translation into protein.
- 2-4. (Canceled).
5. (Previously Presented) A method according to claim 1 wherein said epithelial tissue is selected from the group consisting of breast, esophagus, kidney, prostate, ovary, melanoma and bladder.
6. (Currently Amended) A method according to claim 1 wherein said ~~antisense molecule has the~~ nucleotide sequence appearing in comprises SEQ ID NO: 7.
- 7-8. (Canceled).
9. (Currently Amended) An expression vector encoding an antisense molecule comprising a nucleotide sequence comprising SEQ ID NO: 7 or a fragment thereof that which hybridizes to an RNA sequence of a thrombin receptor protein, wherein said nucleotide sequence consists of between 250 and 600 base pairs.
10. (Currently Amended) A pharmaceutical composition comprising an active factor and a pharmaceutically acceptable carrier, said active factor being an antisense molecule comprising a nucleotide sequence comprising SEQ ID NO: 7 or a fragment thereof that which hybridizes to an RNA sequence of a thrombin receptor, thereby interfering with the process of mRNA translation into protein.

11. (Currently Amended) A pharmaceutical composition according to claim 10 for the ~~treatment of~~ inhibiting invasiveness of metastatic tumor cells.

12-13. (Canceled).

14. (Currently Amended) A pharmaceutical composition according to claim 11 wherein said tumor ~~cell is~~ cells are of epithelial tissue origin.

15. (Original) A pharmaceutical composition according to claim 14 wherein said epithelial tissue is selected from the group consisting of breast, esophagus, kidney, prostate, ovary, melanoma and bladder.

16. (Currently Amended) A pharmaceutical composition according to claim 10 wherein said ~~antisense molecule has the~~ nucleotide sequence ~~appearing in~~ comprises SEQ ID NO: 7.

17-19. (Canceled)

20. (Previously Presented) An antisense molecule comprising SEQ ID NO: 7.

21. (Previously Presented) A method according to claim 1, wherein said antisense molecule is an expression vector containing said nucleotide sequence in an antisense orientation.

22. (Previously Presented) A method according to claim 21, wherein said nucleotide sequence has from 250 to 600 base pairs.

23. (Previously Presented) The pharmaceutical composition according to claim 10, wherein said antisense molecule is an expression vector containing said nucleotide sequence in an antisense orientation.

24. (Previously Presented) A pharmaceutical composition according to claim 23, wherein said nucleotide sequence has from 250 to 600 base pairs.

25-26. (Canceled).

27. (Currently Amended) A method ~~for treating of inhibiting invasiveness of~~ placental cytotrophoblast ~~cells of a subject cells,~~ the method comprising administering to contacting said subject cells with an antisense molecule, ~~said antisense molecule~~ comprising a nucleotide sequence comprising SEQ ID NO: 7 or a fragment thereof that ~~which~~ hybridizes to an RNA sequence of a thrombin receptor, thereby interfering with the process of mRNA translation into proteins.

28. (New) A method according to claim 27, wherein said antisense molecule is an expression vector containing said nucleotide sequence in the antisense orientation.

29. (New) A method according to claim 28, wherein said nucleotide sequence has from 250 to 600 base pairs.